Bolt Biotherapeutics, Inc. (BOLT) investor relations documents from the company's IR site: 1 presentation; latest deck 2026-08-11. Read in-app with summaries. First-party data.
Bolt Biotherapeutics Corporate Overview: Bolt Biotherapeutics is developing BDC-4182, a claudin 18.2-targeting Immune Stimulating Antibody Conjugate (ISAC), with initial clinical data expected in 3Q26.
| Published | Type | Document |
|---|---|---|
| 2026-08-11 | Presentation | Bolt Biotherapeutics Corporate Overview |
BOLT overview · BOLT earnings · BOLT financials · BOLT KPIs · BOLT ownership · BOLT peers · BOLT filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.